Eledon Pharmaceuticals IncNASDAQ:ELDN
- LAST PRICE5.0200
- TODAY'S CHANGE (%)0.1900 (3.9337%)
- Bid / Lots5.0200/ 1
- Ask / Lots5.0300/ 2
- Open / Previous Close4.8200 / 4.8300
- Day Range
- 52 Week Range
- Volume336,717
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ELDN |
|---|---|---|
| 09:32 ET | 3222 | 4.7577 |
| 09:35 ET | 1800 | 4.86 |
| 09:37 ET | 830 | 4.86 |
| 09:39 ET | 2220 | 4.9258 |
| 09:42 ET | 2257 | 4.89 |
| 09:44 ET | 200 | 4.77 |
| 09:48 ET | 200 | 4.79 |
| 09:50 ET | 975 | 4.87 |
| 09:53 ET | 2200 | 4.9599 |
| 09:55 ET | 2574 | 4.905 |
| 09:57 ET | 10320 | 5 |
| 10:00 ET | 5864 | 4.995 |
| 10:02 ET | 210 | 4.99 |
| 10:06 ET | 304 | 4.973663 |
| 10:08 ET | 700 | 4.98 |
| 10:09 ET | 290 | 5.07 |
| 10:11 ET | 200 | 4.98 |
| 10:13 ET | 12476 | 5.165 |
| 10:15 ET | 100 | 5.21 |
| 10:18 ET | 6794 | 5.166 |
| 10:20 ET | 700 | 5.01 |
| 10:22 ET | 6380 | 5.025 |
| 10:24 ET | 200 | 4.98 |
| 10:26 ET | 7196 | 4.925 |
| 10:27 ET | 2609 | 4.95 |
| 10:29 ET | 1704 | 4.9537 |
| 10:31 ET | 354 | 4.96 |
| 10:33 ET | 800 | 5.02 |
| 10:36 ET | 1436 | 4.93 |
| 10:38 ET | 890 | 4.9 |
| 10:40 ET | 400 | 4.93 |
| 10:42 ET | 936 | 4.91 |
| 10:45 ET | 4355 | 4.885 |
| 10:47 ET | 300 | 4.88 |
| 10:49 ET | 3931 | 4.84 |
| 10:54 ET | 510 | 4.9 |
| 10:56 ET | 712 | 4.86 |
| 11:00 ET | 300 | 4.86 |
| 11:02 ET | 510 | 4.86 |
| 11:05 ET | 1300 | 4.88 |
| 11:07 ET | 200 | 4.89 |
| 11:09 ET | 502 | 4.91 |
| 11:12 ET | 200 | 4.91 |
| 11:14 ET | 1400 | 4.88 |
| 11:18 ET | 200 | 4.89 |
| 11:20 ET | 300 | 4.86 |
| 11:23 ET | 200 | 4.89 |
| 11:25 ET | 17515 | 5.01 |
| 11:27 ET | 1152 | 4.98 |
| 11:30 ET | 800 | 4.95 |
| 11:32 ET | 1000 | 4.96 |
| 11:34 ET | 804 | 4.96 |
| 11:36 ET | 1543 | 4.89 |
| 11:38 ET | 5538 | 4.97 |
| 11:39 ET | 2688 | 4.96 |
| 11:41 ET | 200 | 4.98 |
| 11:45 ET | 200 | 4.95 |
| 11:48 ET | 523 | 5.035 |
| 11:50 ET | 600 | 5.05 |
| 11:52 ET | 9100 | 5.25 |
| 11:54 ET | 14112 | 5.19 |
| 11:57 ET | 1501 | 5.1 |
| 11:59 ET | 392 | 5.1 |
| 12:01 ET | 400 | 5.09 |
| 12:03 ET | 200 | 5.07 |
| 12:06 ET | 3550 | 5.055 |
| 12:08 ET | 670 | 5.0616 |
| 12:10 ET | 5175 | 5.04 |
| 12:12 ET | 800 | 5.025 |
| 12:14 ET | 5476 | 5.075 |
| 12:15 ET | 9546 | 5.03 |
| 12:17 ET | 100 | 5.005 |
| 12:19 ET | 500 | 5 |
| 12:21 ET | 900 | 5.005 |
| 12:24 ET | 700 | 5.01 |
| 12:26 ET | 100 | 5.0375 |
| 12:28 ET | 11000 | 5.035 |
| 12:30 ET | 300 | 5.02 |
| 12:32 ET | 100 | 5.035 |
| 12:33 ET | 100 | 5.04 |
| 12:35 ET | 2215 | 5.035 |
| 12:39 ET | 200 | 5.005 |
| 12:42 ET | 1500 | 5.0037 |
| 12:46 ET | 2119 | 5.01 |
| 12:48 ET | 100 | 5.02 |
| 12:50 ET | 200 | 5.02 |
| 12:53 ET | 200 | 5.02 |
| 12:55 ET | 200 | 5.02 |
| 12:57 ET | 474 | 5.0101 |
| 01:00 ET | 1050 | 5.0001 |
| 01:02 ET | 985 | 5 |
| 01:04 ET | 710 | 5 |
| 01:08 ET | 2700 | 5 |
| 01:09 ET | 200 | 5.005 |
| 01:11 ET | 150 | 5.005 |
| 01:13 ET | 1800 | 5.01 |
| 01:15 ET | 200 | 5.01 |
| 01:18 ET | 400 | 5 |
| 01:20 ET | 100 | 5.005 |
| 01:22 ET | 200 | 5 |
| 01:26 ET | 800 | 5.02 |
| 01:27 ET | 300 | 5.02 |
| 01:29 ET | 600 | 5.02 |
| 01:33 ET | 10004 | 5.04 |
| 01:36 ET | 200 | 5.02 |
| 01:38 ET | 967 | 5.02 |
| 01:42 ET | 378 | 5.02 |
| 01:44 ET | 300 | 5.02 |
| 01:45 ET | 6880 | 5.02 |
| 01:47 ET | 300 | 5.02 |
| 01:49 ET | 300 | 5.02 |
| 01:51 ET | 1468 | 5.02 |
| 01:54 ET | 100 | 5.02 |
| 01:56 ET | 318 | 5.015 |
| 01:58 ET | 4645 | 4.96 |
| 02:02 ET | 200 | 4.96 |
| 02:03 ET | 200 | 4.96 |
| 02:05 ET | 300 | 4.96 |
| 02:07 ET | 100 | 5 |
| 02:09 ET | 200 | 4.96 |
| 02:12 ET | 500 | 4.96 |
| 02:14 ET | 100 | 4.99 |
| 02:16 ET | 295 | 4.97 |
| 02:18 ET | 1618 | 4.9799 |
| 02:21 ET | 300 | 4.96 |
| 02:23 ET | 200 | 4.95 |
| 02:25 ET | 4453 | 5.01 |
| 02:27 ET | 1024 | 5.01 |
| 02:32 ET | 1100 | 5.01 |
| 02:36 ET | 200 | 5.005 |
| 02:38 ET | 400 | 5.02 |
| 02:39 ET | 1600 | 5.05 |
| 02:41 ET | 200 | 5.06 |
| 02:45 ET | 3695 | 5.06 |
| 02:48 ET | 600 | 5.06 |
| 02:50 ET | 21058 | 5.1 |
| 02:52 ET | 2100 | 5.1295 |
| 02:54 ET | 2900 | 5.1 |
| 02:56 ET | 600 | 5.1 |
| 02:57 ET | 1294 | 5.13 |
| 02:59 ET | 200 | 5.135 |
| 03:01 ET | 200 | 5.135 |
| 03:03 ET | 1712 | 5.15 |
| 03:06 ET | 1784 | 5.145 |
| 03:08 ET | 2025 | 5.14 |
| 03:10 ET | 300 | 5.125 |
| 03:12 ET | 882 | 5.09 |
| 03:14 ET | 1920 | 5.125 |
| 03:15 ET | 692 | 5.1 |
| 03:17 ET | 1000 | 5.08 |
| 03:19 ET | 400 | 5.09 |
| 03:21 ET | 504 | 5.09 |
| 03:24 ET | 3100 | 5.08 |
| 03:28 ET | 789 | 5.1 |
| 03:30 ET | 400 | 5.08 |
| 03:32 ET | 1218 | 5.09 |
| 03:33 ET | 2394 | 5.06 |
| 03:35 ET | 400 | 5.0883 |
| 03:37 ET | 2515 | 5.0201 |
| 03:39 ET | 100 | 5.02 |
Oct 29, 2024
DJ Eledon Pharmaceuticals Shares Hit 52-Week High After Positive Trial Data, from 1:31PM ET on Tuesday Oct 29, 2024 by Dow Jones
1:31PM ET on Tuesday Oct 29, 2024 by Dow JonesEledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants, from 7:46AM ET on Tuesday Oct 29, 2024 by Dow Jones
7:46AM ET on Tuesday Oct 29, 2024 by Dow Jones*DJ Eledon Pharmaceuticals Announces Pricing of $85M Underwritten Offering of Common Stk and Pre-Funded Warrants, from 7:46AM ET on Tuesday Oct 29, 2024 by Dow Jones
7:46AM ET on Tuesday Oct 29, 2024 by Dow JonesEledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine, from 7:45AM ET on Tuesday Oct 29, 2024 by Dow Jones
7:45AM ET on Tuesday Oct 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Eledon Pharmaceuticals Inc | 274.6M | -2.0x | --- |
Lexeo Therapeutics Inc | 272.4M | -2.9x | --- |
Inozyme Pharma Inc | 277.3M | -2.8x | --- |
Zura Bio Ltd | 278.7M | -8.3x | --- |
Atea Pharmaceuticals Inc | 282.8M | -1.6x | --- |
Zentalis Pharmaceuticals Inc | 265.2M | -1.4x | --- |
Company Information
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
Contact Information
- Headquarters
- 19800 MACARTHUR BLVD., SUITE 250IRVINE, CA, United States 92612
- Phone
- 949-238-8090
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Keith Katkin
- President, Chief Scientific Officer, Director
- Steven Perrin
- Chief Executive Officer, Director
- David-Alexandre Gros
- Chief Financial Officer
- Paul Little
- Chief Compliance Officer, General Counsel, Corporate Secretary
- Bryan Smith
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $274.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 56.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.76 |
EPS | $-2.52 |
Book Value | $3.45 |
P/E Ratio | -2.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
